You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 10,314,910

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,314,910

Title:	Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy
Abstract:	Provided is a method for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with an immunopotentiator (for example, a PD-1 inhibitor).
Inventor(s):	Nathan; Asher (Jerusalem, IL), Shahar; Michal (Rishon Lezion, IL)
Assignee:	NeoTX Therapeutics Ltd. (Rehovot, IL)
Application Number:	15/402,888
Patent Claims:	1. A method of treating a cancer in a subject in need thereof, the method comprising: administering to the subject (i) an effective amount of a superantigen conjugate comprising a first protein chain comprising SEQ ID NO: 8 and a second protein chain comprising SEQ ID NO: 9 that together bind a 5T4 cancer antigen expressed by cancerous cells within the subject and (ii) an effective amount of an anti-PD-1 antibody selected from nivolumab and pembrolizumab, thereby to treat the cancer, wherein the cancer is selected from non-small cell lung cancer and melanoma. 2. The method of claim 1, wherein the superantigen conjugate is administered to the subject before the anti-PD-1 antibody. 3. The method of claim 1, wherein the anti-PD-1 antibody is pembrolizumab. 4. The method of claim 1, wherein the anti-PD-1 antibody is nivolumab. 5. The method of claim 1, wherein the cancer is non-small cell lung cancer. 6. The method of claim 1, wherein the cancer is melanoma. 7. The method of claim 1, wherein the superantigen conjugate is administered to the subject at the same time as the anti-PD-1 antibody. 8. The method of claim 1, wherein the superantigen conjugate is administered to the subject after the anti-PD-1 antibody.

Details for Patent 10,314,910

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	For Injection	125514	09/04/2014	⤷ Try a Trial	2036-01-10
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	Injection	125514	01/15/2015	⤷ Try a Trial	2036-01-10
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	12/22/2014	⤷ Try a Trial	2036-01-10
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	10/04/2017	⤷ Try a Trial	2036-01-10
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	08/27/2021	⤷ Try a Trial	2036-01-10
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.